Lineage Cell Therapeutics to Present at LD Micro 500 Investor Conference and Solebury Trout Zoomside Chat on September 1, 2020
August 25 2020 - 08:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
therapies for unmet medical needs, announced today that Brian M.
Culley, Chief Executive Officer, will be presenting at the LD Micro
500 Virtual Investor Conference on September 1, 2020 at 9:40 am
Eastern Time / 6:40 am Pacific Time.
Brian M. Culley and Brandi L. Roberts, Chief Financial Officer,
will also be participating in the 2020 Solebury Trout Zoomside Chat
on September 1, 2020 at 12:00 pm Eastern Time / 9:00 am Pacific
Time. The Solebury Trout conference format will consist of fireside
chats between participating companies and covering analysts.
Lineage management will participate in a fireside chat hosted by
Joseph Pantginis, Ph.D., Managing Director, Equity Research, H.C.
Wainwright & Co., LLC.
Interested investors can access both live presentations on the
Events and Presentations section of Lineage’s website and archived
presentations will be available for 30 days. Additional videos are
available on the Media page of the Lineage website, located at
www.lineagecell.com/media/.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its robust proprietary cell-based
therapy platform and associated in-house development and
manufacturing capabilities. With this platform Lineage develops and
manufactures specialized, terminally differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed to either replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury or administered as a means of helping the body
mount an effective immune response to cancer. Lineage’s clinical
programs are in markets with billion dollar opportunities and
include three allogeneic (“off-the-shelf”) product candidates: (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
1/2a development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a
development for the treatment of acute spinal cord injuries; and
(iii) VAC, an allogeneic dendritic cell therapy platform for
immuno-oncology and infectious disease, currently in clinical
development for the treatment of non-small cell lung cancer and in
preclinical development for additional cancers and as a vaccine
against infectious diseases, including SARS-CoV-2, the virus which
causes COVID-19. For more information, please visit
www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200825005144/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (442) 287-8963
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2023 to Mar 2024